Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Condition:   Recurrent or Progressive Glioblastoma Interventions:   Drug: Bevacizumab;   Drug: Bevacizumab with chemo;   Radiation: Fractionated radiosurgery Sponsor:   Henry Ford Health System Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials